Converting Mutant p53 into an Actionable Target for the Treatment of Ovarian Cancer
Abstract
Our specific aims are to 1) in a retrospective study of GOG/NRG 218 clinical samples, determine the functional class of TP53 mutation for each case and correlate with response; 2) assess the mechanisms of resistance to therapy as defined by outcomes from GOG/NRG 218 and identify alternative molecularly enhanced combinations; and 3) interrogate the function of TP53 mutations that are somatic variants of unknown function to define the best therapy for patients with these mutations. These studies are anticipated to have a significant positive impact on the field by enhancing the design and choice of therapy for ovarian cancer based on specific TP53 mutations. Moreover, our findings have the potential for immediate clinical application since we are performing retrospective analyses of a positive trial to better define a subgroup of patients that are more likely to respond. We will also prioritize drug choice in Aims 2 and 3 to use agents that have proven safety profiles and efficacy in other cancer types. Hence, our findings can be quickly implemented to provide personalized precision treatment options and improve outcomes for women with ovarian cancer using currently defined and FDA-approved treatments.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1215414
Entities
People
- Kimberly K Leslie
Organizations
- University of New Mexico